Eli Lilly
Lilly to Submit Data on Potential New Kisunla Dosing for Early Symptomatic Alzheimer's
ARIA-E was observed in 14 percent of patients who received a modified dosing regimen, compared to 24 percent of patients who received standard dosing.
FDA Grants Full Approval to Eli Lilly's Retevmo in RET-Mutant Medullary Thyroid Cancer
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
In Brief This Week: UniQure, WHO, Vertex, Lonza, Elixirgen, Eli Lilly, ClearNote Health, Penn State
News items for the week of Sept. 23, 2024.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
The company drew on data from prior studies and simulations to show what happens when patients stop receiving the beta-amyloid-targeting drug.